VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | The potential of targeting dihydroorotate dehydrogenase in CML

Giuseppe Saglio, MD, University of Turin, Turin, Italy, comments on the potential of targeting dihydroorotate dehydrogenase (DHODH) in chronic myeloid leukemia (CML), explaining that combining DHODH inhibition with other existing therapeutic strategies might improve the number of patients eligible for tyrosine kinase inhibitor (TKI) discontinuation. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter